Auris Medical, a Swiss-French biotechnology company developing specific treatments for inner ear disorders, reported the results of the first clinical trial with the investigational otoprotective drug AM-111. The double blind, randomised clinical trial involving two sites in Germany was conducted in early 2006 to evaluate the safety of AM-111 in the treatment of acute sensorineural hearing loss (ASNHL). Study results show that AM-111 was well tolerated by all patients and provide first indications of a therapeutic effect of this novel otoprotective drug.
